Charcot-Marie-Tooth disease type 2S is an inherited neuromuscular condition with an estimated global prevalence of less than one in one million. The disorder triggers chronic sensory and motor impairment, often resulting in severe physical disability and the loss of the ability to walk. Vanda is currently developing VCA-894A to address a specific genetic variant of the disease, a target identified in a patient diagnosed at an early age.

Mihael H. Polymeropoulos, CEO of Vanda, stated that the designation acknowledges the significant unmet medical need for families facing limited treatment options. The FDA’s decision allows Vanda to potentially qualify for a priority review voucher upon the future approval of a marketing application, a program designed to incentivize the development of therapies for serious pediatric conditions. The company continues to coordinate with federal regulators as it advances the clinical development program for the drug.